Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II

NCT04618211 is registered in ClinicalTrials.gov with Pharvaris Netherlands B.V. as lead sponsor.

NCT NCT04618211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04618211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II
Lead sponsor
Pharvaris Netherlands B.V.
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2021
Completion date
March 1, 2023
Enrollment
74 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

c1 esterase inhibitor deficiency, c1 inhibitor deficiency, hereditary angioedema, hereditary angioedema - type 1, hereditary angioedema - type 2, hereditary angioedema attack, hereditary angioedema type i, hereditary angioedema type ii, hereditary angioedema types i and ii, hereditary angioedema with c1 esterase inhibitor deficiency